Brain Tumors

Tailored Therapy in Diffuse Gliomas

We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.

Brain Tumors

A history of hormonal contraceptive use in younger women for 5 years or more was found to be associated with a possible increased risk of glioma.

The recent evidence that incorporation of chemotherapeutic interventions can result in relatively long survival times for patients with low-grade glioma highlights the need to also preserve neurocognitive function and health-related quality of life in these patients.

In this article, we provide a brief overview of the management of grade II astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas—the three most heavily encountered and studied of the low-grade gliomas.

As our understanding of tumor biology grows, we may identify targeted agents that can be used to treat low-grade gliomas. One such approach moving into clinical trials is the use of IDH inhibitors.

There have been and continue to be areas of uncertainty surrounding the treatment of grade II gliomas. One in particular is the optimal timing of treatment.

Depressive symptoms and impaired executive functioning, both common in patients with glioblastoma, are independently associated with shorter overall survival.

A core set of symptoms are common across brain tumor patients and underscore the complexity of brain tumors and their management.


Subscribe to Brain Tumors on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.